Health authorities in Taiwan say lung cancer is now the most common form of cancer in the country, surpassing colorectal cancer. Although cancer rates are down overall, it remains the leading ...
GlobalData on MSN8d
Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trialThe US company has launched dosing in Taiwan for its Phase II trial of LP-300. In the US, some patients saw 51% tumour ...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platfo ...
Texas-based artificial intelligence (AI) oncology firm, Lantern Pharma, has dosed the first patient from Taiwan in a Phase II trial of LP-300 in never-smoker patients with non-small cell lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback